This article is more than 5 years old. Information may no longer be current.

DaVita HealthCare Partners names new CFO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DaVita HealthCare Partners Inc., the parent company of dialysis provider DaVita, has named Garry E. Menzel, PhD, chief financial officer, effective after Sept. 30. He will act as senior vice president of finance until then.

Menzel, 48, most recently held the positions of Chief Operating Officer and Chief Financial Officer at Regulus Therapeutics Inc., a publicly-traded biopharmaceutical company. Prior to joining Regulus in 2008, he had a 14-year career on Wall Street where he was a managing director and global head of life sciences for Credit Suisse and a managing director and global head of biotechnology for Goldman Sachs. Menzel also spent several years as a strategy consultant for Bain & Company. 

Menzel earned a B.Sc. in biochemistry from the Imperial College of Science & Technology in London, England, a PhD in molecular biology from the University of Cambridge, England, and a Masters in Business Administration from the Stanford Graduate School of Business. 

Jim Hilger, who has served as Interim Chief Financial Officer since 2012, and acting chief financial officer from 2007 to 2008, will continue in his role as the company’s chief accounting officer, a position he has held since 2010.